Prognostic Role of Cyclin D2/D3 in Multiple Human Malignant Neoplasms: A Systematic Review and Meta-analysis

Overview

Journal Cancer Med

Specialty Oncology

Date 2019 Apr 6

PMID 30950241

Citations 27

Authors

Zuo-You Ding

Ran Li

Qi-Jie Zhang

Yi Wang

Yi Jiang

Qing-Yang Meng

Qiu-Lei Xi

Guo-Hao Wu

Affiliations

Soon will be listed here.

Abstract

Cyclin D2/D3 (CCND2/3) are core components of the machinery that drives cell cycle progression and therefore, are associated with tumorigenesis. Currently, there are contradictory evidences on the function of CCND2/3 in tumorigenesis. Thus, we conducted a comprehensive meta-analysis to derive a precise predictive value of CCND2/3 in various tumors. We searched PubMed, EMBASE, Web of Science for eligible studies up to October 8, 2018. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) of OS or DFS/PFS/RFS were calculated using Forest plot analysis to demonstrate their associations. A total of 14 studies were ultimately included in this meta-analysis. Our results indicated CCND2/3 played an oncogenic role in all of the cancer patients (CCND2: pooled HR = 2.21, 95% CI: 1.67-2.93; CCND3: pooled HR = 2.29, 95% CI: 1.05-5.03). In tumor subgroup, CCND2 was associated with shorter OS in patients with gastric cancer (HR = 2.20, 95% CI: 1.66-2.92), whereas it might be a tumor suppressor in NSCLC (HR = 0.28, 95% CI: 0.12-0.64). In addition, CCND3 was correlated to reduced OS in breast cancer patients (HR = 1.64, 95% CI: 1.07-2.52) and shorter DFS/PFS/RFS in bladder cancer patients (HR = 4.60, 95% CI: 1.89-12.57). Taken together, CCND2/3 could be the promising biomarkers for predicting the prognosis of patients with malignant neoplasms.

Citing Articles

A Necessary Role for Cyclin D2 Induction During Colon Cancer Progression Mediated by L1.

Saha A, Gavert N, Brabletz T, Ben-Zeev A Cells. 2024; 13(21.

PMID: 39513917 PMC: 11544798. DOI: 10.3390/cells13211810.

Establishment and characterization of cytochrome P450 1A1 CRISPR/Cas9 Knockout Bovine Foetal Hepatocyte Cell Line (BFH12).

Iori S, DOnofrio C, Laham-Karam N, Mushimiyimana I, Lucatello L, Lopparelli R Cell Biol Toxicol. 2024; 40(1):18.

PMID: 38528259 PMC: 10963470. DOI: 10.1007/s10565-024-09856-7.

Functional characterization of cooperating MGA mutations in RUNX1::RUNX1T1 acute myeloid leukemia.

Thomas 3rd M, Qi W, Walsh M, Ma J, Westover T, Abdelhamed S Leukemia. 2024; 38(5):991-1002.

PMID: 38454121 PMC: 11073986. DOI: 10.1038/s41375-024-02193-y.

Pharmacological EZH2 inhibition combined with retinoic acid treatment promotes differentiation and apoptosis in rhabdomyosarcoma cells.

OBrien E, Tse C, Tracy I, Reddin I, Selfe J, Gibson J Clin Epigenetics. 2023; 15(1):167.

PMID: 37858275 PMC: 10588044. DOI: 10.1186/s13148-023-01583-w.

Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling.

Cardona-Benavides I, Misiewicz-Krzeminska I, Rojas E, de Ramon C, Sanz-Solas A, Isidro I Haematologica. 2023; 109(3):877-887.

PMID: 37646661 PMC: 10905080. DOI: 10.3324/haematol.2023.283445.

References

Lopez-Beltran A, Luque R, Alvarez-Kindelan J, Quintero A, Merlo F, Carrasco J . Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1). Eur Urol. 2004; 45(5):606-12. DOI: 10.1016/j.eururo.2003.11.011. View

Takano Y, Kato Y, Masuda M, Ohshima Y, Okayasu I . Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis. J Pathol. 1999; 189(2):194-200. DOI: 10.1002/(SICI)1096-9896(199910)189:2<194::AID-PATH426>3.0.CO;2-P. View

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

Yu J, Leung W, Ebert M, Leong R, Tse P, Chan M . Absence of cyclin D2 expression is associated with promoter hypermethylation in gastric cancer. Br J Cancer. 2003; 88(10):1560-5. PMC: 2377112. DOI: 10.1038/sj.bjc.6600940. View

Ding Z, Li R, Zhang Q, Wang Y, Jiang Y, Meng Q . Prognostic role of cyclin D2/D3 in multiple human malignant neoplasms: A systematic review and meta-analysis. Cancer Med. 2019; 8(6):2717-2729. PMC: 6558476. DOI: 10.1002/cam4.2152. View

Ren B, Li W, Yang Y, Wu S . The impact of cyclin D1 overexpression on the prognosis of bladder cancer: a meta-analysis. World J Surg Oncol. 2014; 12:55. PMC: 3973981. DOI: 10.1186/1477-7819-12-55. View

Mitra R, Lee J, Jo J, Milani M, McClintick J, Edenberg H . Prediction of postoperative recurrence-free survival in non-small cell lung cancer by using an internationally validated gene expression model. Clin Cancer Res. 2011; 17(9):2934-46. PMC: 3086939. DOI: 10.1158/1078-0432.CCR-10-1803. View

Zhang Q, Sakamoto K, Liu C, Triplett A, Lin W, Rui H . Cyclin D3 compensates for the loss of cyclin D1 during ErbB2-induced mammary tumor initiation and progression. Cancer Res. 2011; 71(24):7513-24. PMC: 3242818. DOI: 10.1158/0008-5472.CAN-11-1783. View

Levidou G, Korkolopoulou P, Thymara I, Vassilopoulos I, Saetta A, Gakiopoulou H . Expression and prognostic significance of cyclin D3 in ovarian adenocarcinomas. Int J Gynecol Pathol. 2007; 26(4):410-7. DOI: 10.1097/pgp.0b013e31804630a7. View

10.

Takano Y, Kato Y, van Diest P, Masuda M, Mitomi H, Okayasu I . Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol. 2000; 156(2):585-94. PMC: 1850035. DOI: 10.1016/S0002-9440(10)64763-3. View

11.

He X, Chen S, Yang Z, Zhang J, Wang W, Liu M . miR-4317 suppresses non-small cell lung cancer (NSCLC) by targeting fibroblast growth factor 9 (FGF9) and cyclin D2 (CCND2). J Exp Clin Cancer Res. 2018; 37(1):230. PMC: 6145328. DOI: 10.1186/s13046-018-0882-4. View

12.

Mermelshtein A, Gerson A, Walfisch S, Delgado B, Shechter-Maor G, Delgado J . Expression of D-type cyclins in colon cancer and in cell lines from colon carcinomas. Br J Cancer. 2005; 93(3):338-45. PMC: 2361572. DOI: 10.1038/sj.bjc.6602709. View

13.

Goel S, Wang Q, Watt A, Tolaney S, Dillon D, Li W . Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell. 2016; 29(3):255-269. PMC: 4794996. DOI: 10.1016/j.ccell.2016.02.006. View

14.

Malumbres M, Barbacid M . Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009; 9(3):153-66. DOI: 10.1038/nrc2602. View

15.

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

16.

Bouchard C, Thieke K, Maier A, Saffrich R, Ansorge W, Reed S . Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 1999; 18(19):5321-33. PMC: 1171602. DOI: 10.1093/emboj/18.19.5321. View

17.

Ko E, Kim Y, Park S, Cho E, Han J, Shim Y . Reduced expression of cyclin D2 is associated with poor recurrence-free survival independent of cyclin D1 in stage III non-small cell lung cancer. Lung Cancer. 2012; 77(2):401-6. DOI: 10.1016/j.lungcan.2012.03.027. View

18.

He Q, Wu J, Liu X, Ma Y, Wu X, Wang W . Clinicopathological and prognostic significance of cyclin D1 amplification in patients with breast cancer: a meta-analysis. J BUON. 2017; 22(5):1209-1216. View

19.

Santarius T, Shipley J, Brewer D, Stratton M, Cooper C . A census of amplified and overexpressed human cancer genes. Nat Rev Cancer. 2009; 10(1):59-64. DOI: 10.1038/nrc2771. View

20.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View